» Articles » PMID: 30602972

Secondary Hyperparathyroidism Among Nigerians with Chronic Kidney Disease

Overview
Journal Afr Health Sci
Date 2019 Jan 4
PMID 30602972
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Backround: Secondary hyperparathyroidism (SHPT) is a manifestation of chronic kidney disease mineral bone disorder (CKD-MBD). SHPT is common in patients with chronic kidney disease (CKD) and is associated with significant morbidity and mortality.

Methods: A cross- sectional descriptive study involving 230 patients with CKD.

Results: The mean age of the study population was 44.17±15.24 years. The median intact parathyroid hormone and alkaline phosphatase levels were 96pg/ml (range 4-953pg/ml) and 88 iu/l (range 10-800 iu/l) respectively. The mean (with standard deviation) calcium, serum phosphate, calcium phosphate product and haemoglobin levels were 2.22±0.29mmol/l, 1.8±0.62mmol/l, 3.94±1.42mmol/l and 9.90±1.87g/dl respectively. Majority of patients had advanced CKD with 70.3% of patients in stage G5. The prevalence rates of SHPT, hypocalcaemia, hyperphosphataemia, elevated alkaline phosphatase and elevated calcium phosphate product were 55.2%, 34.8%, 66.1%, 42.2% and 25.2% respectively.Univariate analysis revealed that SHPT was associated with hypocalcaemia, hyperphosphataemia, elevated alkaline phosphatase, proteinuria, anaemia, hypertension, left ventricular hypertrophy and stage of kidney disease; being worse with advancing kidney disease. Independently associated with SHPT were hypocalcaemia (OR=4.84), hyperphosphataemia (OR=3.06), and elevated alkaline phosphatase (OR=2.04).

Conclusion: The prevalence of SHPT in CKD is high, occurs early and is independently associated with hypocalcaemia, hyperphosphataemia and elevated alkaline phosphatase. The prevalence of SHPT also increases with worsening renal function.

Citing Articles

Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.

Wang Y, Liu J, Fang Y, Zhou S, Liu X, Li Z Front Endocrinol (Lausanne). 2024; 15:1400891.

PMID: 38974573 PMC: 11224516. DOI: 10.3389/fendo.2024.1400891.


Influencing factors of cardiac valve calcification (CVC) in patients with chronic kidney disease and the impact of CVC on long-term prognosis: a single-center retrospective study.

Wang J, Xiao J, Wang R, Wang D PeerJ. 2023; 11:e15569.

PMID: 37404480 PMC: 10317020. DOI: 10.7717/peerj.15569.


Risk Factor Analysis and Prediction of Severe Hypocalcemia after Total Parathyroidectomy without Auto-Transplantation in Patients with Secondary Hyperparathyroidism.

He C, Zhang Y, Li L, Cheng G, Zhang W, Tang Y Int J Endocrinol. 2023; 2023:1901697.

PMID: 36700169 PMC: 9870689. DOI: 10.1155/2023/1901697.


Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.

Raji Y, Ajayi S, Adeoye A, Amodu O, Tayo B, Salako B Afr Health Sci. 2022; 22(1):344-351.

PMID: 36032486 PMC: 9382529. DOI: 10.4314/ahs.v22i1.42.


Sexuality and other issues in Africa and beyond.

Tumwine J Afr Health Sci. 2019; 18(2):i-iii.

PMID: 30602976 PMC: 6306960. DOI: 10.4314/ahs.v18i2.1.

References
1.
Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

2.
Kovesdy C, Ahmadzadeh S, Anderson J, Kalantar-Zadeh K . Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008; 73(11):1296-302. DOI: 10.1038/ki.2008.64. View

3.
Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

4.
Odenigbo U, Ijoma C, Ulasi I, Udeh A, Ibeh C . The prevalence of radiological markers of renal osteodystrophy in patients with chronic renal failure in Enugu. Niger J Clin Pract. 2007; 9(2):147-52. View

5.
Sanusi A, Arogundade F, Oladigbo M, Ogini L, Akinsola A . Prevalence and pattern of renal bone disease in end stage renal disease patients in Ile-Ife, Nigeria. West Afr J Med. 2010; 29(2):75-80. DOI: 10.4314/wajm.v29i2.68201. View